EGFR and cancer: Finally, the parallel signaling axes we describe suggest that in some contexts, EGFR inhibitors may show combinatorial benefit with VEGF pathway inhibitors, whereby the EGFR inhibitor both impairs cancer cell survival and reduces pericyte coverage, with the latter rendering the tumor endothelium more sensitive to VEGFR inhibition.